GSK Begins Shipping Influenza Vaccine Doses For 2024-25 Season, Expects To Distribute Over 36M Doses Of Its Trivalent Influenza Vaccines In The U.S. This Season

Author: Benzinga Newsdesk | July 11, 2024 08:08am

• GSK supports annual flu immunization by getting FLULAVAL and FLUARIX to patients in advance of flu season

GSK plc (NYSE:GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA).

In February 2024, the World Health Organization (WHO) recommended the removal of B/Yamagata strains from seasonal influenza vaccines.1 The WHO recommends that egg-based trivalent vaccines for the 2024-2025 northern hemisphere influenza season contain the following:1

• A/Victoria/4897/2022 (H1N1)pdm09-like virus
• A/Thailand/8/2022 (H3N2)-like virus
• B/Austria/1359417/2021 (B/Victoria lineage)-like virus

In partnership with regulatory bodies, GSK worked quickly to ensure production, approval and availability of trivalent influenza vaccines with the recommended composition for the 2024-25 flu season.

GSK expects to distribute over 36 million doses of its trivalent influenza vaccines in the US this season. Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months of age and older.

Posted In: GSK